Shared care for Malignancies

Phase-Based Progress Estimates
Physical activity - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial will test whether a shared care model, with regularly scheduled visits with an oncologist and a clinical exercise physiologist, will increase physical activity levels, functional capacity, and quality of life for cancer patients.

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Month 0 (first visit), month 1, month 3, month 6, month 9, month 12

Month 12
Walk Test
Functional Assessment of Cancer Therapy - General (FACT-G QOL) measurement.
International Physical Activity Questionnaire (IPAQ) score
Patient Health Questionnaire 9 (PHQ-9) score

Trial Safety

Trial Design

2 Treatment Groups

Standard of care
1 of 2
Shared care
1 of 2
Active Control

120 Total Participants · 2 Treatment Groups

Primary Treatment: Shared care · No Placebo Group · N/A

Standard of careNoIntervention Group · 1 Intervention: Standard of care · Intervention Types:
Shared care
ActiveComparator Group · 1 Intervention: Physical activity · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 0 (first visit), month 1, month 3, month 6, month 9, month 12

Who is running the clinical trial?

Gundersen Health SystemOTHER
1 Previous Clinical Trials
2,404 Total Patients Enrolled
Landspitali University HospitalLead Sponsor
37 Previous Clinical Trials
461,369 Total Patients Enrolled
1 Trials studying Malignancies
120 Patients Enrolled for Malignancies
Agnes Smaradottir, MDPrincipal InvestigatorLandspitali University Hospital

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
This means that the patient is considered to have a good performance status.
rates across states Pathologic confirmed cancer diagnosis rates vary greatly from state to state.
Patients who are receiving adjuvant treatment with the goal of curing their cancer are likely to have a better outcome than those who do not receive adjuvant treatment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: October 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.